# RCloud Tasking Form – Part B: Statement of Requirement (SoR)

| | |
|---|---|
| **Title of Requirement** | Determination of utility of the Bilosome platform for oral delivery of I.V formulation drugs |
| **Requisition No.** | As stated in the RCloud Portal |
| **SoR Version** | **0.1** |

| **1.** | **Statement of Requirements** |
|---|---|
| **1.1** | **Summary and Background Information** |
| | Dstl require I.V Formulation antibiotics to be administered via the oral route. This will require the development of the Bilosome technology. This will require the modification of existing bilosome technology. |
| **1.2** | **Requirement** |
| | Redacted under FOI Exemption 22A – Research Information<br>Task 1. To determine if the oral uptake of bilosomes can be improved by the addition of at least 2 different ligands Redacted under FOI Exemption 22A – Research Information<br><br>Task 2. To determine in vitro and ex vivo antimicrobial activity of bilosome formulations. Bacterial MIC assays will be used to determine drug activity post formulation Redacted under FOI Exemption 22A – Research Information |
| **1.3** | **Options or follow on work** *(if none, write 'Not applicable')* |
| | |
| **1.4** | **Contract Management Activities** |
| | Once the contract is placed, there will be a start-up project meeting held virtually at contract award. From then on, there will be monthly calls with UoS to monitor progress by the Technical Lead at DSTL, with emails detailing progress made following each meeting.<br><br>It is anticipated that this piece of work will last : |

| | |
|---|---|
| | Task 1: 6 – 12 months<br><br>Task 2: 6 - 12 months<br><br>Following completion of Task 1 - The contractor is to provide an interim report, with a final report due upon completion of Task 2. These will be technically reviewed prior to payment.<br><br>Technical and Final report will be delivered in 2024. The final report is due for delivery on or before 31/01/2024.<br><br>UoS will be using their own bilosome technology which has already been established. |
| **1.5** | **Health & Safety, Environmental, Social, Ethical, Regulatory or Legislative aspects of the requirement** |
| | Any in vivo work must be covered by an appropriate Home Office Licence. All laboratory work must be covered by organisationally approved risk assessments and standard operating procedures. |

| 1.6 | Deliverables & Intellectual Property Rights (IPR) | | | | | |
|---|---|---|---|---|---|---|
| **Ref.** | **Title** | **Due by** | **Format** | **Expected classification (subject to change)** | **What information is required in the deliverable** | **IPR Condition** |
| *D - 1* | Interim report for Task 1 | *T0+6 Months* | *Report* | *OS* | *Report to include but not limited to:*<br>*• Update on technical progress against task 1*<br>• *To include Introduction, Materials & Methods, results and conclusions.*<br>• *Work should be able to be replicated externally from the level of information provided.* | *Default RCloud Agreement Terms and Conditions shall apply* |
| *D - 2* | Final report | T0 +21 Months | Report | OS | Report to include but not limited to:<br>• To include all results generated for Tasks 1 and 2.<br>• *To include Introduction, Materials & Methods, results and conclusion sections.*<br>• *Work should be able to be replicated externally from the level of information* | *Default RCloud Agreement Terms and Conditions shall apply* |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | *provided.* | |
| | | | | | | |

| 1.7 | **Deliverable Acceptance Criteria** |
|---|---|
| | Final reports shall describe the entire work performed under each task, on the Contract and in sufficient detail to explain comprehensively the work undertaken and results achieved. |

| 2 | **Evaluation Criteria** |
|---|---|
| 2.1 | Method Explanation |
| | This work is a continuation of work completed by University of Strathclyde under RCloud tasking form – 1000152346 which was contracted on 01 Jun 2020.<br>Where data is to be further exploited. Consistency in performer is therefore required for data comparison, including in vivo testing, thus ethical considerations |
| 2.2 | Technical Evaluation Criteria |
| | |
| 2.3 | Commercial Evaluation Criteria |
| | |